Advertisement

Abstract

Although oncogenic driver mutations in RAS occur in 20% of cancers, heterogeneity in the biologic outputs of different RAS mutants has hampered efforts to develop effective treatments for RAS-mutated cancers. In this issue of Science Signaling, Huynh et al. show that even among KRASQ61 mutants, the specific amino acid that is substituted substantially affects mutant KRAS biologic activity and oncogenicity.

Get full access to this article

View all available purchase options and get full access to this article.

Already a subscriber or AAAS Member? Log In

REFERENCES AND NOTES

1
E. Sheffels, N. E. Sealover, C. Wang, D. H. Kim, I. A. Vazirani, E. Lee, E. M. Terrell, D. K. Morrison, J. Luo, R. L. Kortum, Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation. Sci. Signal. 11, eaar8371 (2018).
2
E. M. Terrell, D. E. Durrant, D. A. Ritt, N. E. Sealover, E. Sheffels, R. Spencer-Smith, D. Esposito, Y. Zhou, J. F. Hancock, R. L. Kortum, D. K. Morrison, Distinct binding preferences between Ras and Raf family members and the impact on oncogenic Ras signaling. Mol. Cell 76, 872–884.e5 (2019).
3
J. C. Hunter, A. Manandhar, M. A. Carrasco, D. Gurbani, S. Gondi, K. D. Westover, Biochemical and structural analysis of common cancer-associated KRAS mutations. Mol. Cancer Res. 13, 1325–1335 (2015).
4
M. H. Hofmann, M. Gmachl, J. Ramharter, F. Savarese, D. Gerlach, J. R. Marszalek, M. P. Sanderson, D. Kessler, F. Trapani, H. Arnhof, K. Rumpel, D. A. Botesteanu, P. Ettmayer, T. Gerstberger, C. Kofink, T. Wunberg, A. Zoephel, S. C. Fu, J. L. Teh, J. Böttcher, N. Pototschnig, F. Schachinger, K. Schipany, S. Lieb, C. P. Vellano, J. C. O’Connell, R. L. Mendes, J. Moll, M. Petronczki, T. P. Heffernan, M. Pearson, D. McConnell, N. Kraut, BI-3406, a potent and selective SOS1-KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition. Cancer Discov. 11, 142–157 (2021).
5
C. W. Johnson, Y.-J. Lin, D. Reid, J. Parker, S. Pavlopoulos, P. Dischinger, C. Graveel, A. J. Aguirre, M. Steensma, K. M. Haigis, Isoform-specific destabilization of the active site reveals a molecular mechanism of intrinsic activation of KRas G13D. Cell Rep. 28, 1538–1550.e7 (2019).
6
J. H. Cook, G. E. M. Melloni, D. C. Gulhan, P. J. Park, K. M. Haigis, The origins and genetic interactions of KRAS mutations are allele- and tissue-specific. Nat. Commun. 12, 1808 (2021).
7
M. V. Huynh, G. A. Hobbs, A. Schaefer, M. Pierobon, L. M. Carey, J. N. Diehl, J. M. DeLiberty, R. D. Thurman, A. R. Cooke, C. M. Goodwin, J. H. Cook, L. Lin, A. M. Waters, N. U. Rashid, E. F. Petricoin III, S. L. Campbell, K. M. Haigis, D. M. Simeone, C. A. Lyssiotis, A. D. Cox, C. J. Der, Functional and biological heterogeneity of KRASQ61 mutations. Sci. Signal. 15, eabn2694 (2022).
8
Y. Kobayashi, C. Chhoeu, J. Li, K. S. Price, L. A. Kiedrowski, J. L. Hutchins, A. I. Hardin, Z. Wei, F. Hong, M. Bahcall, P. C. Gokhale, P. A. Jänne, Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers. Nature 603, 335–342 (2022).
9
G. A. Hobbs, N. M. Baker, A. M. Miermont, R. D. Thurman, M. Pierobon, T. H. Tran, A. O. Anderson, A. M. Waters, J. N. Diehl, B. Papke, R. G. Hodge, J. E. Klomp, C. M. Goodwin, J. M. DeLiberty, J. Wang, R. W. S. Ng, P. Gautam, K. L. Bryant, D. Esposito, S. L. Campbell, E. F. Petricoin III, D. K. Simanshu, A. J. Aguirre, B. M. Wolpin, K. Wennerberg, U. Rudloff, A. D. Cox, C. J. der, Atypical KRASG12R mutant is impaired in PI3K signaling and macropinocytosis in pancreatic cancer. Cancer Discov. 10, 104–123 (2020).
10
S. Li, C. M. Counter, Signaling levels mold the RAS mutation tropism of urethane. eLife 10, e67172 (2021).

Information & Authors

Information

Published In

View large Science Signaling cover image
Science Signaling
Volume 15 | Issue 746
August 2022

Submission history

Received: 13 June 2022
Accepted: 15 July 2022

Permissions

Request permissions for this article.

Acknowledgments

We thank B. Daley for comments and reading of the manuscript.
Funding: The Kortum laboratory is supported by funding from the NCI (1R01CA255232 and 1R21CA267515), the CDMRP Lung Cancer Research Program (LC180213 and LC210123), and a CRADA from Boehringer Ingelheim. The opinions and assertions expressed herein are those of the authors and are not to be construed as reflecting the views of Uniformed Services University of the Health Sciences or the United States Department of Defense.
Competing interests: The Kortum laboratory receives funding from Boehringer Ingelheim to study SOS1 as a therapeutic target in RAS-mutated cancers.

Authors

Affiliations

Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
Roles: Conceptualization, Investigation, Methodology, Visualization, Writing - original draft, and Writing - review & editing.
Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
Roles: Conceptualization, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing - original draft, and Writing - review & editing.

Notes

*
Corresponding author. Email: [email protected]

Metrics & Citations

Metrics

Article Usage
Altmetrics

Citations

Export citation

Select the format you want to export the citation of this publication.

View Options

Check Access

Log in to view the full text

AAAS ID LOGIN

AAAS login provides access to Science for AAAS Members, and access to other journals in the Science family to users who have purchased individual subscriptions.

Log in via OpenAthens.
Log in via Shibboleth.

More options

Purchase access to this article

Download and print this article within 24 hours for your personal scholarly, research, and educational use.

View options

PDF format

Download this article as a PDF file

Download PDF

Media

Figures

Multimedia

Tables

Share

Share

Share article link

Share on social media

(0)eLetters

eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. eLetters are not edited, proofread, or indexed. Please read our Terms of Service before submitting your own eLetter.

Log In to Submit a Response

No eLetters have been published for this article yet.